Gilead Keeps Climbing Out Of Veklury’s Shadow As Core Business Growth Strengthens

 
• By Alaric DeArment
  
Generate a summary of this article
Listen to this article
Beta

Sales of the COVID-19 antiviral continued their long decline, but even when factoring those in, Gilead’s overall revenue increased by 5% year-over-year.

• Source: Shutterstock

Gilead Sciences, Inc. showed a strengthening of its core business in the second quarter of 2023 as sales climbed higher even when factoring in the COVID-19 antiviral drug Veklury (remdesivir), which had carried Gilead’s sales during the pandemic and whose declines had in multiple quarters caused the company’s revenues to fall, remain flat or rise only slightly on a year-over-year basis.

The Foster City, CA-based company released its second quarter sales on 3 August, reporting revenue of $6.6bn, up from $6.3bn...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.